Ozempic-like drugs have more benefits to the body than just losing weight, meta-analysis shows. A meta-analysis of 10 randomized controlled trials involving more than 23,000 participants, presented at the International Congress on Obesity (ICO 2026), hosted by the World Obesity Federation (WOF) in Mexico City, Mexico (July 15–17), shows that the GLP-1 class of obesity drugs is associated with a marked reduction in systemic inflammation beyond its anti-obesity effects, potentially explaining how the drugs can reduce cardiovascular risk factors.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: A meta-analysis of 10 randomized controlled trials involving more than 23,000 participants, presented at the International Congress on Obesity (ICO 2026), hosted by the World Obesity Federation (WOF) in Mexico City, Mexico (July 15–17), shows that the GLP-1 class of obesity drugs is associated with a marked reduction in systemic inflammation beyond its anti-obesity effects, potentially explaining how the drugs can reduce cardiovascular risk factors.
- Ponto de atenção: ozempic.
- Ponto de atenção: like.
- Ponto de atenção: drugs.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
